Point-of-Care Chemistry-Guided Dialysate Adjustment to Reduce Arrhythmias: A Pilot Trial

Patrick H Pun1,2, Michele Santacatterina3, Javaughn Ways4

  • 1Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

PubMed
Abstract

Insights

Point-of-care testing for dialysate potassium and bicarbonate adjustment in hemodialysis is feasible and safe. This approach may help reduce arrhythmias by managing electrolyte and acid-base balance more precisely during treatment.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Chemistry

Background:

  • Excessive removal of potassium (K) and acid during hemodialysis (HD) increases arrhythmia risk.
  • Treatment-to-treatment dialysate modification is infrequently implemented.
  • Point-of-care (POC) testing offers a potential solution for real-time adjustments.

Purpose of the Study:

  • To evaluate the safety, feasibility, and efficacy of four POC chemistry-guided protocols for adjusting dialysate K and bicarbonate (HCO3).
  • To assess the impact of these protocols on electrolyte and acid-base variability and arrhythmia rates in outpatient HD.

Main Methods:

  • A multicenter pilot randomized study involving 19 subjects.
  • Participants underwent four 4-week crossover periods with dialysate K or HCO3 adjustments based on pre-HD POC values.
  • Protocols included K-removal minimization/maximization and acidosis/alkalosis avoidance.
  • Implantable cardiac loop monitors tracked clinically significant arrhythmias (CSAs).

Main Results:

  • HD staff successfully adjusted dialysate in 85% of treatments.
  • No serious adverse events related to interventions were reported.
  • High intertreatment variability in K and HCO3 was observed.
  • Numerically fewer CSAs occurred during alkalosis avoidance and K-removal maximization periods.

Conclusions:

  • Algorithm-guided K/HCO3 adjustment using POC testing is feasible in HD clinics.
  • The observed variability highlights the potential for POC-guided algorithms to significantly alter dialysate-serum chemistry gradients.
  • Further endpoint-powered trials are warranted to confirm efficacy.

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Pulse rhythm01:30

Pulse rhythm

Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
807
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594